Theriva Biologics (TOVX) announced selection as one of five finalists for Merck KGaA’s EMEA Advance Biotech Grant. Finalists for the grant will present to a six-judge panel from Merck’s Emerging Biotech group during BIO Europe 2024 in Stockholm, Sweden. Manel Cascallo, PhD., General Director – EU Subsidiary, Theriva Biologics, will present an overview of VCN-01, currently being studied in a Phase 2b clinical trial in first-line metastatic pancreatic cancer in combination with standard-of-care chemotherapy. Dr Cascallo will highlight VCN-01’s novel mechanisms of action and Theriva’s internal capabilities to develop its manufacturing process in his presentation on Monday, November 4…
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva Biologics Gains Orphan Drug Status for VCN-01
- Theriva announces orphan medicinal product designation by EMA to VCN-01
- Theriva Biologics’ SYN-004 receives positive DSMC review in Phase 1/2 trial
- Theriva Biologics Advances SYN-004 in Clinical Trial
- Theriva Biologics prices $2.5M public offering at $1.75 per share